ATR vs EMBJ: How AptarGroup and Embraer Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ATR and EMBJ share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ATR and EMBJ exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AptarGroup makes the precision dispensing and drug-delivery systems that sit on top of everyday products: nasal spray and inhaler valves for pharma, pumps and airless systems for fragrance and skincare, and dispensing and non-dispensing closures for food, beverage, personal care, and home care. The company runs three reporting segments (Pharma, Beauty, and Closures), with Pharma generating the bulk of profit thanks to long-cycle, regulated, high-margin drug-delivery contracts. Aptar serves a global customer base and positions itself around active material science and delivery precision rather than commodity packaging.

Full ATR guide

Embraer S.A. is a global aerospace company headquartered in Sao Paulo that designs and builds aircraft across four reported segments. Commercial Aviation covers the E1 and E2 families of jets up to about 150 seats, where Embraer sits behind Airbus and Boeing but effectively owns the sub-150-seat category. Executive Aviation sells the light Phenom and midsize Praetor business jets. Defense and Security builds the C-390/KC-390 Millennium multi-mission transport and the A-29 Super Tucano light attack and trainer aircraft. Services and Support is the aftermarket arm covering maintenance, parts pooling and engine overhaul, and it carries the highest margin of the four. A smaller Others segment holds agricultural aviation, the Tempest cyber unit and a landing-gear business, and the majority-owned Eve Holding eVTOL venture is consolidated but carved out of guidance. Embraer delivered 244 aircraft in 2025 on revenue of ~$7.58 billion and has shipped more than 9,000 aircraft since 1969.

Full EMBJ guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ATR drivers: High-margin pharma drug delivery; Beauty and consumer recovery.
• EMBJ drivers: Converting a record backlog into deliveries; Defense and Security turning from drag to contributor.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Core organic sales have been roughly flat, so headline growth has leaned on acquisitions and currency, which is lower-quality growth. For EMBJ, deliveries are concentrated in the back half of the year, so a supply chain slip on engines or structures in the fourth quarter can move the full-year result materially, and Embraer has limited room to catch up once a quarter is lost.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ATR if you believe its drivers more; EMBJ if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ATR and EMBJ guides.

ATR. Aptar trades like a quality defensive industrial: a mid-20s earnings multiple, a low beta near 0.4, and a 30-plus year dividend-growth record. The key valuation tension is paying a premium multiple for a business whose organic sales are currently near flat, so the case depends on pharma mix, margin recovery, and eventual beauty and closures reacceleration.

EMBJ. Embraer had not yet reported second-quarter 2026 financials as of early August, with the release scheduled for August 10, so the latest full income statement is 1Q26: revenue of ~$1,447 million, up ~31% and the highest first quarter on record, adjusted EBIT of ~$94.0 million at a ~6.5% margin, and adjusted net income of ~$27.7 million. The ADSs are up substantially over the past year and sit inside a 52-week range of roughly $54 to $81, with average sell-side price targets near $81. The trailing multiple looks demanding against a business earning single-digit EBIT margins, which is largely why the forward figure compresses to the low twenties on the guided ramp.

Headline figures (approximate, July 2026): ATR shows revenue (ttm) ~$3.9B, q1 2026 sales ~$983M (+11% reported, ~flat core), q1 2026 adjusted eps ~$1.19, market cap ~$8.6B; EMBJ shows revenue (ttm) ~$7.9 billion (four quarters through 1Q26; FY2025 was ~$7.58 billion, up ~18%), 2026 revenue guidance ~$8.2 billion to ~$8.5 billion, adjusted ebit margin ~8.7% in FY2025, guided ~8.7% to ~9.3% for 2026, firm order backlog ~$34.5 billion as of 2Q26, a seventh consecutive record.

ATR and EMBJ are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ATR and EMBJ exposure against your real portfolio. It is not an investment adviser.